WEBULL
WebtradeDownload

Can Revvity (RVTY) Turn Decentralized Prenatal Screening Into a Durable Diagnostics Advantage?

Simply Wall St · 1d ago
  • Earlier in August 2026, Revvity, Inc. launched the SuperFlex prenatal screening system, a compact, CE-IVDR certified immunoassay platform designed to deliver rapid, high-quality preeclampsia and biochemical prenatal testing for lower-volume laboratories and clinics across CE-markets, with Asia-Pacific rollout planned for late 2026.
  • By enabling decentralized, random-access prenatal screening with minimal reagent waste and LifeCycle software integration, SuperFlex directly broadens access to guideline-recommended preeclampsia testing that has historically been concentrated in high-throughput central labs.
  • Next, we'll examine how SuperFlex’s focus on decentralized, software-integrated prenatal screening could influence Revvity’s diagnostics-driven investment narrative.

Uncover the next big thing with 22 elite penny stocks that balance risk and reward.

Revvity Investment Narrative Recap

To be comfortable owning Revvity, you need to believe that its mix of diagnostics and software can turn modest revenue growth into healthier earnings over time, despite margin pressure and past profit volatility. The SuperFlex launch strengthens the reproductive health and prenatal diagnostics story, but it does not immediately change the key near term swing factors: pressures on diagnostics pricing in markets like China and the company’s dependence on cost actions to support earnings.

Among recent announcements, the integration of Revvity Signals software with Anthropic’s Model Context Protocol stands out alongside SuperFlex, because both highlight a push toward software enabled, higher value workflows. If Signals can keep compounding its recurring revenue base while new instruments like SuperFlex expand test menus and consumables use, that combination could matter more for future margins than any single product launch.

Yet while SuperFlex may broaden prenatal testing access, investors should still be aware of how vulnerable Revvity’s diagnostics margins remain if reimbursement policies tighten further...

Read the full narrative on Revvity (it's free!)

Revvity's narrative projects $3.4 billion revenue and $554.4 million earnings by 2029. This requires 4.9% yearly revenue growth and an earnings increase of about $317 million from $237.4 million today.

Uncover how Revvity's forecasts yield a $121.07 fair value, a 3% downside to its current price.

Exploring Other Perspectives

RVTY 1-Year Stock Price Chart
RVTY 1-Year Stock Price Chart

Some of the most optimistic analysts were already assuming revenue above US$3.3 billion and earnings near US$456.8 million by 2029, yet the SuperFlex launch and concerns about diagnostics pricing power could easily shift those expectations in different directions, reminding you that informed investors can reasonably land on very different views of Revvity’s future.

Explore 3 other fair value estimates on Revvity - why the stock might be worth as much as 22% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Ready To Venture Into Other Investment Styles?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.